scholarly journals Clinical Predictors of Persistent Mediastinal Nodal Disease After Induction Therapy for Stage IIIA N2 Non-Small Cell Lung Cancer

2017 ◽  
Vol 103 (1) ◽  
pp. 281-286 ◽  
Author(s):  
Mohamed K. Kamel ◽  
Mohamed Rahouma ◽  
Galal Ghaly ◽  
Abu Nasar ◽  
Jeffrey L. Port ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Induction Therapy ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Nodal Disease ◽  
Small Cell Lung ◽  
Clinical Predictors ◽  
Stage Iiia

OA20.04 Survival of Patients with Persistent N1 or N2 Disease After Induction Therapy for Stage IIIA-N2 Non-Small-Cell Lung Cancer

2021 ◽  
Vol 16 (10) ◽  
pp. S884
Author(s):  
J. Beqari ◽  
A. Potter ◽  
M. Pan ◽  
J. Copeland ◽  
M. Lanuti ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Induction Therapy ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Stage Iiia ◽  
N2 Disease

Gemcitabine and Cisplatin as Induction Regimen for Patients With Biopsy-Proven Stage IIIA N2 Non–Small-Cell Lung Cancer: A Phase II Study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955)

2000 ◽  
Vol 18 (14) ◽  
pp. 2658-2664 ◽  
Author(s):  
N. Van Zandwijk ◽  
E.F. Smit ◽  
G.W. P. Kramer ◽  
F. Schramel ◽  
S. Gans ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Induction Chemotherapy ◽  
Induction Therapy ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
World Health ◽  
Small Cell Lung ◽  
Stage Iiia ◽  
Induction Regimen

PURPOSE: Our objective was to better define the activity/feasibility of gemcitabine/cisplatin (GC) as induction chemotherapy in patients with stage IIIA N2 non–small-cell lung cancer (NSCLC) followed by surgery or radiotherapy within a large, ongoing comparative study (EORTC 08941). PATIENTS AND METHODS: Forty-seven chemotherapy-naive patients with NSCLC, median age of 58 years, stage IIIA N2 disease, World Health Organization performance status of 0 or 1, and the ability to tolerate a pneumonectomy received gemcitabine 1,000 mg/m2 on days 1, 8, and 15 and cisplatin 100 mg/m2 on day 2, every 4 weeks. Patients received induction chemotherapy (three cycles) before re-evaluation and randomization to surgery or radiotherapy. RESULTS: Grade 3/4 thrombocytopenia, the main hematologic toxicity, occurred in 60% of patients but was not associated with bleeding. Full-dose gemcitabine was given in 48% of the courses. Severe nonhematologic toxicity was uncommon. Two patients with preexisting, autoimmune pulmonary fibrosis had deterioration of pulmonary function after radiotherapy. Thirty-three (70.2%; 95% confidence interval, 55.1% to 82.7%) of the 47 eligible patients had objective responses (three complete responses and 30 partial responses). Mediastinal nodes were tumor-free after induction therapy in 53% of cases. Resections were considered complete in 71% of the patients who underwent thoracotomy after induction therapy. Median survival for all recruited patients (N = 53) was 18.9 months, with an estimated 1-year survival rate of 69%. CONCLUSION: In patients with N2 stage IIIA NSCLC, GC is a highly active and well-tolerated induction regimen. GC should be explored in combination with surgery or radiotherapy in stage I and II patients.

scholarly journals Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer

2017 ◽  
Vol 103 (4) ◽  
pp. 1070-1075 ◽  
Author(s):  
Pamela Samson ◽  
Traves D. Crabtree ◽  
Cliff G. Robinson ◽  
Daniel Morgensztern ◽  
Stephen Broderick ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Induction Therapy ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Time Interval ◽  
Small Cell Lung ◽  
Stage Iiia ◽  
The Ideal

PHYSICIAN PREFERENCES FOR MANAGEMENT OF PATIENTS WITH STAGE IIIA NON-SMALL CELL LUNG CANCER: IMPACT OF BULK OF NODAL DISEASE ON THERAPY SELECTION

CHEST Journal ◽  
2008 ◽  
Vol 134 (4) ◽  
pp. 44P
Author(s):  
Mark R. Green ◽  
Laura Daniels ◽  
Joanne Willey ◽  
Louis Iovino ◽  
Susanne Giebner ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Nodal Disease ◽  
Small Cell Lung ◽  
Stage Iiia

scholarly journals Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non–Small-Cell Lung Cancer

2018 ◽  
Vol 14 (9) ◽  
pp. 569-571 ◽  
Author(s):  
Addie Hill ◽  
Jun Gong ◽  
Sharon Wilczynski ◽  
Rizvan Mirza ◽  
Loretta Erhunmwunsee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Pathologic Response ◽  
Complete Pathologic Response ◽  
Small Cell Lung ◽  
Stage Iiia
Sign in / Sign up

Export Citation Format

Share Document